Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

Abstract Background We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified. Methods Pretreatment FFPE tumor specimens (n = 26) were stained for CD8, PD-L1,...

Full description

Bibliographic Details
Main Authors: Nicolas A. Giraldo, Peter Nguyen, Elizabeth L. Engle, Genevieve J. Kaunitz, Tricia R. Cottrell, Sneha Berry, Benjamin Green, Abha Soni, Jonathan D. Cuda, Julie E. Stein, Joel C. Sunshine, Farah Succaria, Haiying Xu, Aleksandra Ogurtsova, Ludmila Danilova, Candice D. Church, Natalie J. Miller, Steve Fling, Lisa Lundgren, Nirasha Ramchurren, Jennifer H. Yearley, Evan J. Lipson, Mac Cheever, Robert A. Anders, Paul T. Nghiem, Suzanne L. Topalian, Janis M. Taube
Format: Article
Language:English
Published: BMJ Publishing Group 2018-10-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
PD-1
PD-L1
Merkel cell
Multispectral immunofluorescence
Pembrolizumab
Online Access:http://link.springer.com/article/10.1186/s40425-018-0404-0

Internet

http://link.springer.com/article/10.1186/s40425-018-0404-0

Similar Items